Meeting
2020 ASCO Virtual Scientific Program
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.
Authors
Neeraj Agarwal
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Neeraj Agarwal , Yohann Loriot , Bradley Alexander McGregor , Robert Dreicer , Tanya B. Dorff , Benjamin Louis Maughan , William Kevin Kelly , Lance C. Pagliaro , Sandy Srinivas , Christian Michael Squillante , Ulka N. Vaishampayan , Evelyn W. Wang , Dominic Curran , Toni K. Choueiri , Sumanta K. Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03170960
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5564)
DOI
10.1200/JCO.2020.38.15_suppl.5564
Abstract #
5564
Poster Bd #
145
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study.
First Author: Neeraj Agarwal
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
First Author: Srikala S. Sridhar
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
First Author: Henry Jacob Conter